Lasting recovery from insomnia that’s available anytime, anywhere.

Illustration of Sleepio's sleep diary

In a clinical trial, 76% of patients experienced clinically significant improvement in insomnia


reduction in time to fall asleep.1


less time awake at night.1


better functioning the next day.1

For the past decade, we’ve been putting Sleepio to the test in 13 randomised control clinical trials.
We’re trusted by the NHS because we take evidence seriously. Learn more about our industry-leading commitment to research:

Sleepio is the first-ever digital treatment to receive positive guidance from NICE

NICE have recommended Sleepio as an effective first-line digital treatment for insomnia, to be considered before the prescription of sleeping pills or sleep hygiene.2

Sleepio delivers meaningful, lasting results

Sleepio uses evidence-based Cognitive Behavioural Therapy (CBT) techniques to address unique needs with a programme tailored to the individual, featuring sessions with step-by-step guidance. In about 20 minutes per week, individuals can quiet their racing minds, reshape behaviours, and get better sleep.

Image depicting the wind-down, before-sleep schedule screen from Sleepio.

Tailored therapeutic content

Sleepio adjusts therapeutic content to each individual’s needs and offers additional tools and insights when needed.

Image depicting Sleepio's "Help me get to sleep" menu of sleep aids.

Help at any time, day or night

When it’s needed the most, Sleepio is instantly accessible and ready to check in, practise, or try a new technique.

Image depicting a Sleepio progress chart.

Progress tracking

Sleepio provides personalised goal setting, a detailed sleep diary, and helps track progress over time.

What Sleepio users say

Sleepio has made a huge change in my ability to fall asleep quickly and have restful sleep.

Sleepio User, UKSeptember, 2020

Using this program is like having a friend that understands your anxiety around sleep and helps you through it.

Member in AfricaNovember, 2020

I’ve had insomnia for 18 years. Sleepio has brought my average sleep from two hours a night to seven hours a night.

Member in UKOctober, 2020

I can’t believe I learned so much in such a short time after suffering for decades. This program is brilliant.

Member in USApril, 2021

Poor sleep affects up to a third of UK adults 

Sleep problems may affect up to a third of the UK population and most sleep-wake disorders, for example shift work sleep disorder, are likely underdiagnosed.3 Due to limited availability of CBT, patients and clinicians are often left with no choice but to use commonly-prescribed sleep medications. Evidence shows these have limited long-term effectiveness and can cause side effects like drowsiness and memory loss.4

1. Espie, C. A., Kyle, S. D., Williams, C., Ong, J. C., Douglas, N. J., Hames, P., & Brown, J. S. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769-781.
2. Miller, C. B., Carl, J. R., Henry, A. L., Baker, L. (2020). A health economic evaluation of Sleepio at a Fortune 500 company. Retrieved from:
3. CDC – Data and Statistics – Sleep and Sleep Disorders. (2017). CDC.
4. Varkevisser, M., & Kerkhof, G. A. (2005). Chronic insomnia and performance in a 24‐h constant routine study. Journal of Sleep Research, 14(1), 49-59.
5. Shahly, V., Berglund, P. A., Coulouvrat, C., Fitzgerald, T., Hajak, G., Roth, T., … & Kessler, R. C. (2012). The associations of insomnia with costly workplace accidents and errors: results from the America Insomnia Survey. Archives of general psychiatry, 69(10), 1054-1063.
6. Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalder, K., Johann, A., … & Baglioni, C. (2019). Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep medicine reviews, 43, 96-105.
7. Brandt, J., & Leong, C. (2017). Benzodiazepines and Z-drugs: an updated review of major adverse outcomes reported on in epidemiologic research. Drugs in R&D, 17(4), 493-507.